Skip to main content

All Policy Documents

 Abdominoplasty/Apronectomy following Significant Weight Loss, Policy Position Statement (PP45), July 2013 (PDF, 578Kb)
 Adult Congenital Heart Disease Services (Levels 1 and 2) for people aged 16 and over, Service Specification (CP214). June 2022 (PDF, 423Kb)
 Adult Neurosurgery, Service Specification, (CP178), February 2023 (PDF, 731Kb)
 All Wales Posture and Mobility, Service Specification (CP59). April 2017 (PDF, 1.5Mb)
 Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policy (CP224). November 2021 (PDF, 443Kb)
 Alternative and Augmentative Communication (AAC), Commissioning Policy (CP93a), May 2019 (PDF, 570Kb)
 Asfotase Alfa for Treating Paediatric Onset Hypophosphatasia (PP156).pdf (PDF, 284Kb)
 Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene (CP118) (PDF, 247Kb)
 Balloon Pulmonary Angioplasty (PP162).pdf (PDF, 207Kb)
 Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022 (PDF, 277Kb)
 Bleeding Disorders (All Ages), Service Specification (CP77), June 2022 (PDF, 343Kb)
 Body Contouring, Commissioning Policy (CP44). July 2013 (PDF, 691Kb)
 Brachytherapy in the Treatment of Localised Prostate Cancer, Commissioning Policy (CP01). September 2022 (PDF, 368Kb)
 Breast Surgery Procedures, Commissioning Policy (CP69). March 2013 (PDF, 342Kb)
 Burosumab for Treating X-linked Hypophosphataemia in Children and Young People, Policy Position (PP177), May 2019.pdf (PDF, 557Kb)
 Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 and older), Policy Position Statement, (PP228). January 2022. (PDF, 324Kb)
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome or Lennox–Gastaut syndrome in people aged 2 years and older (PP203), February 2021 (PDF, 545Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Gilead Axicabtagene Ciloleucel (Yescarta®) Service Specification (CP175). March 2019 (PDF, 514Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Novartis Tisagenlecleucel (Kymriah ®) Service Specification. (CP176). March 2019 (PDF, 571Kb)
 Chimeric Antigen Receptor T Cell (CAR T) Therapy, Policy Position Statement, (PP185). October 2021 (PDF, 369Kb)
 Circumcision for Children, Commissioning Policy (CP34). March 2019 (PDF, 344Kb)
 Cleft Lip and or Palate including Non-Cleft Velopharyngeal Dysfunction All Ages (CP186) (PDF, 680Kb)
 Clinical Trials (CP164) (PDF, 284Kb)
 Cochlear implant for children and adults with severe to profound deafness (CP35) (PDF, 259Kb)
 Complex Devices Implantable Cardioverter Defibrillators and Cardiac Resynchronisation Therapy for arrhythmias and heart failure (PP151).pdf (PDF, 240Kb)
 Crizanlizumab for Preventing Sickle Cell Crisis in Sickle Cell Disease (SCD) in people aged 16 and over, Policy Position Statement (PP234), February 2023 (PDF, 281Kb)
 Cystic Fibrosis Modulator therapies Policy Position Statement, (PP198). March 2022 (PDF, 354Kb)
 Cystic Fibrosis: Adults and Young People (CP193), Service Specification. Jan 2021 (PDF, 658Kb)
 Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis and Pseudomyxoma Peritonei, Policy Position Statement, (PP90). September 2015 (PDF, 239Kb)
 Deep Brain Stimulation (CP28) (PDF, 421Kb)
 Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
 Drug Treatment for Lysosomal Storage Disorders (All ages), Commissioning Policy (CP55). January 2023 (PDF, 420Kb)
 Eating Disorder Specialised Services Tier 4, Commissioning Policy (CP20). November 2011 (PDF, 320Kb)
 Eculizimab for Atypical Haemolytic Uraemic Syndrome (aHUS) (CP98) (PDF, 319Kb)
 Eculizumab in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), Commissioning Policy (CP152). February 2019 (PDF, 404Kb)
 Electrophysiology and Ablation Services (16 years and older), Commissioning policy (CP197a). January 2021 (PDF, 713Kb)
 Electrophysiology and Ablation Services (16 years and older), Service Specification (CP197b) January 2021 (PDF, 619Kb)
 Emicizumab as prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages), Policy Position Statement (PP167). November 2018 (PDF, 316Kb)
 Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189). August 2019 (PDF, 246Kb)
 Enhanced Image Guided Brachytherapy (IGBT) Service for the Treatment of Gynaecological Malignancies, Commissioning Policy (CP75). May 2017 (PDF, 723Kb)
 PP103 Everolimus for the prevention of organ rejection following heart transplantation.pdf (PDF, 164Kb)
 Extra corporeal membrane oxygenation (ECMO) service for adults with cardiac failure, Policy Position Statement, (PP102). July 2019 (PDF, 141Kb)
 Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplant (BTLT) (All Ages), Policy Position Statement, (PP251), February 2023 (PDF, 288Kb)
 Extracorporeal Photophoresis (ECP )for treatment of Chronic Graft Versus Host Disease GVHD in Adults Commissioning Policy, (CP91). November 2015 (PDF, 231Kb)
 Extracorporeal Photophoresis (ECP) for T Cell lymphoma, Commissioning Policy (CP92). November 2015 (PDF, 192Kb)
 Facial Surgery procedures, Commissioning Policy (CP43). July 2013 (PDF, 329Kb)
 Facial Surgery procedures: Referral proforma Blepharoplasty (CP43) (Word, 92Kb)
 Facial Surgery procedures: Referral proforma Face lift/brow lift (CP43) (Word, 92Kb)
 Facial Surgery procedures: Referral proforma Miscellaneous (CP43) (Word, 91Kb)
 Facial Surgery procedures: Referral proforma Pinnaplasty (CP43) (Word, 91Kb)
 Facial Surgery procedures: Referral proforma Rhinoplasty (CP43) (Word, 92Kb)
 Gatekeeping, Placement and Case Management for Specialised Mental Health Services, CP232, June 2022 (PDF, 399Kb)
 Gender Identity Service for Adults (non surgical) Commissioning Policy (CP182a) (PDF, 541Kb)
 Gender Identity Service for Adults (non surgical) Service Specification (CP182b) (PDF, 578Kb)
 Genomics Service Specification (CP99). June 2022 (PDF, 572Kb)
 Genomic Testing, Policy Position Statement, (PP184). June 2020 (PDF, 231Kb)
 Haematopoietic stem cell transplantation for adults, Service Specification (CP79). January 2020 (PDF, 295Kb)
 Haematopoietic stem cell transplantation, Policy Position Statement, (PP142). January 2020 (PDF, 553Kb)
 Hepatobiliary Surgery, Service Specification (CP73). November 2021 (PDF, 344Kb)
 Home administered Parenteral Nutrition (HPN), Commissioning Policy (CP24). August 2014 (PDF, 732Kb)
 Hyperbaric Oxygen Therapy Policy, Commissioning Policy (CP07). June 2021 (PDF, 304Kb)
 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei, Commissioning Policy (CP02). September 2015 (PDF, 301Kb)
 In-patient Child and Adolescent Mental Health Services (CAMHS): General Adolescent Unit (GAU) and High-Dependency Unit (HDU), Service Specification CP150. July 2021 (PDF, 613Kb)
 Live Donor Expenses (CP30) (PDF, 293Kb)
 Lutetium (177Lu) oxodotreotide for people with neuroendocrine tumours (NETs), Policy Position Statement, (PP195). September 2020 (PDF, 367Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Commissioning Policy (CP87b). August 2015 (PDF, 501Kb)
 Lymphovenous Anastamosis (LVA) microsurgery for Primary and Secondary Lymphoedema, Service Specification (CP87a). August 2015 (PDF, 380Kb)
 Major Trauma Centre, Service Specification (CP188), February 2021 (PDF, 665Kb)
 Mechanical Thrombectomy for the treatment of acute Ischaemic Stroke, Commissioning Policy (CP168). March 2022 (PDF, 816Kb)
 Microprocessor controlled prosthetic knees, Commissioning Policy (CP218). December 2021 (PDF, 388Kb)
 National Acute Porphyria, Service Specification (CP166). February 2019 (PDF, 274Kb)
 National Alternative and Augmentative Communication (AAC) Specialised Aids (CP93), May 2019 (PDF, 264Kb)
 New Treatment Fund (CP159) (PDF, 367Kb)
 Nusinersen for treating spinal muscular atrophy, Policy Position Statement, (PP191). January 2022 (PDF, 399Kb)
 Bariatric Surgery Commissioning Policy (CP29a).pdf (PDF, 316Kb)
 Bariatric Surgery Service Specification (CP29b). (PDF, 383Kb)
 Odevixibat for Treating Progressive Familial Intrahepatic Cholestasis, Policy Position Statement, (PP249), February 2023 (PDF, 193Kb)
 Paediatric Endocrinology (CP163) (PDF, 283Kb)
 Paediatric Epilepsy, Commissioning Policy (CP174), September 2022 (PDF, 487Kb)
 Paediatric Nephrology Service Specification, CP169 (March 2021) (PDF, 443Kb)
 Paediatric Neurological Rehabilitation (Specialised) (CP160) (PDF, 469Kb)
 PP155 Pasireotide for Cushing's Disease.pdf (PDF, 252Kb)
 Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors (NET) in Adults, Service Specification, (CP266), March 2023 (PDF, 300Kb)
 Percutaneous Mitral Valve Leaflet repair for primary degenerative mitral regurgitation in adults, Policy Position Statement (PP206). June 2021 (PDF, 476Kb)
 Perinatal post-mortem investigation of fetal and neonatal deaths (England, Scotland and Wales). Interim Clinical Commissioning Urgent Policy Statement. October 2022 (PDF, 304Kb)
 Personalised External Aortic Root Support (PEARS) for surgical management of enlarged aortic root (adults), Policy Position Statement, (PP104). March 2019 (PDF, 195Kb)
 Pipeline Embolisation Devices used for the treatment of Intracranial Aneurysms (Complex Giant or Large Intracranial Aneurysms), Commissioning Policy (CP101). July 2015 (PDF, 619Kb)
 Plerixafor Stem Cell Mobilisation, Policy Position Statement (PP154). July 2019 (PDF, 299Kb)
 Positron Emission Tomography (PET) Commissioning Policy (CP50a), July 2022 (PDF, 353Kb)
 Positron Emission Tomography (PET), Service Specification (CP50b). September 2020 (PDF, 514Kb)
 PP187 Treatment Options for Transthyretin Amyloidosis in Adults.pdf (PDF, 389Kb)
 Preimplantation Genetic Diagnosis (PGD), Commissioning Policy (CP37). August 2014 (PDF, 736Kb)
 Prosthetic Provision, Service Specification (CP89). March 2022 (PDF, 433Kb)
 Proton Beam Therapy for adults with cancer, Commissioning Policy (CP147). January 2018 (PDF, 321Kb)
 Proton Beam Therapy for children, teenagers and young adults (TYA) with cancer, Commissioning Policy (CP148). January 2018 (PDF, 303Kb)
 Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Commissioning Policy (CP183a). May 2020 (PDF, 318Kb)
 Radiofrequency Ablation (RFA) for the Management of Barrett's Oesophagus, Service Specification (CP183b). May 2020 (PDF, 348Kb)
 Recreational and Sport Prosthetics for a Child or Young Adult up to the age of 25, Commissioning Policy (CP221). November 2021 (PDF, 402Kb)
 Risdiplam for Spinal Muscular Atrophy for people aged under 16 years, Policy Position Statement (PP240). May 2022 (PDF, 361Kb)
 Rituximab and Eculizumab for the Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in people with Hereditary Anaemias, Policy Position Statement (PP237), February 2023 (PDF, 438Kb)
 Salvage Cryotherapy for Prostate Cancer, Policy Position Statement, (PP173). June 2020 (PDF, 188Kb)
 Sapropterin for treating hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders, Policy Position (PP223), January 2023 (PDF, 464Kb)
 Selective internal radiation therapies (SIRT) for treating adults with hepatocellular carcinoma, Policy Position Statement, (PP227). November 2021 (PDF, 303Kb)
 Selexipag for the Treatment of Pulmonary Arterial Hypertension (Adults), Policy Position (PP105), March 2019.pdf (PDF, 255Kb)
 Services for Children with Cancer (CP86) (PDF, 585Kb)
 Sickle Cell Disorders, Thalassaemia Disorders and other Rare Hereditary Anaemias, Service Specification (CP179). December 2020 (PDF, 494Kb)
 Soft Tissue Sarcoma, Service Specification (CP149). June 2020 (PDF, 396Kb)
 South Wales Neonatal Transport Operational Delivery Network, (CP244) October 2022 (PDF, 303Kb)
 Specialised Immunology, Service Specification (CP78). April 2014 (PDF, 950Kb)
 Neuropsychiatric Rehabilitation (Specialised), (CP128).pdf (PDF, 327Kb)
 Specialised Paediatric Rheumatology Service Specification (CP172). November 2021 (PDF, 475Kb)
 Specialist Fertility Services, Commissioning Policy (CP38). July 2018 (PDF, 476Kb)
 Specialist Perinatal Mental Health Inpatient Service (Mother and Baby Unit) CP201, Service Specification. April 2021 (PDF, 474Kb)
 Specialist Spinal Cord Injury Rehabilitation, Commissioning Policy (CP141). March 2018 (PDF, 438Kb)
 Specialist Neurological Rehabilitation, Commissioning Policy (CP140). March 2018 (PDF, 433Kb)
 Spinal Services Operational Delivery Network (CP241) June 2022 (PDF, 381Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) for the management of surgically inoperable Non-Small Cell Lung Cancer in Adults, Commissioning Policy (CP76). May 2014 (PDF, 312Kb)
 Stereotactic Ablative Body Radiotherapy (SABR) Service Specification (CP219) June 2021 (PDF, 356Kb)
 Stereotactic ablative radiotherapy (SABR) for patients with hepatocellular carcinoma (HCC) (Adults), Commissioning Policy (CP124), December 2021 (PDF, 398Kb)
 Stereotactic Ablative Radiotherapy (SABR) in the treatment of Oligometastatic disease, Commissioning Policy (CP121). October 2021 (PDF, 387Kb)
 Stereotactic Radiosurgery for Adults, Teenagers and Young Adults (TYA) (CP22) (PDF, 389Kb)
 Temporary Dialysis Away From Base (DAFB) Holiday Dialysis (CP33).pdf (PDF, 500Kb)
 Thoracic Surgery, Service Specification (CP144). September 2020 (PDF, 448Kb)
 Tofacitinib for treating juvenile idiopathic arthritis in people aged 2 to 16 years, Policy Position Statement (PP229). May 2022 (PDF, 311Kb)
 Trans-catheter Aortic Valve Implantation (TAVI) for Severe Symptomatic Aortic Stenosis (SSAS) (CP58) (PDF, 258Kb)
 Trauma Operational Delivery Network, Service Specification (CP199). February 2021 (PDF, 663Kb)
 Treatment of Benign Skin Conditions, Referral Proforma Resurfacing (CP42) (Word, 91Kb)
 Vagal Nerve Stimulation, Commissioning Policy (CP23). August 2014 (PDF, 238Kb)
 Volanesorsen for treating familial chylomicronaemia syndrome, Policy Position Statement, (PP217). October 2021 (PDF, 285Kb)
 Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease, Policy Position Statement (PP215), May 2021 (PDF, 329Kb)
 PP196 Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations.pdf (PDF, 277Kb)
 War Veterans - Enhanced Prosthetic Provision, Commissioning Policy (CP49). October 2020 (PDF, 415Kb)
 Welsh Artificial Eye Service (WAES) (All Ages), Service Specification (CP238), December 2022 (PDF, 453Kb)